Sinovac Biotech Ltd. Stock Upgraded (SVA)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Sinovac Biotech (Nasdaq: SVA) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • SVA's very impressive revenue growth greatly exceeded the industry average of 9.4%. Since the same quarter one year prior, revenues leaped by 86.3%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The current debt-to-equity ratio, 0.38, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 3.68, which clearly demonstrates the ability to cover short-term cash needs.
  • SINOVAC BIOTECH LTD reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SINOVAC BIOTECH LTD reported poor results of -$0.29 versus -$0.02 in the prior year. This year, the market expects an improvement in earnings (-$0.18 versus -$0.29).
  • The gross profit margin for SINOVAC BIOTECH LTD is currently very high, coming in at 85.02%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, SVA's net profit margin of 7.55% is significantly lower than the industry average.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, SINOVAC BIOTECH LTD's return on equity significantly trails that of both the industry average and the S&P 500.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Sinovac Biotech has a market cap of $251.8 million and is part of the health care sector and drugs industry. Shares are up 45.5% year to date as of the close of trading on Friday.

You can view the full Sinovac Biotech Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

3 Biotech Stocks Under $10 in Breakout Territory

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China

Sinovac Biotech Ltd. Stock Downgraded (SVA)

Sinovac Biotech Ltd. Stock Upgraded (SVA)

Rev Shark: An Odd Market Day